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Abstract
For several complex intracellular pathogens, we have an urgent need for
effective vaccines and yet there are common barriers to vaccine development.
These diseases, including tuberculosis, leishmaniasis, leprosy and melioidosis,
cause a huge burden of disease and disproportionately affect low and middle
income countries. They are therefore often neglected due to the marginalisation
of affected populations and the poor predicted commercial return on
investment. Barriers to vaccine development include an incomplete
understanding of protective immunity and translation from the bench into
clinical vaccine trials. The current linear approach to vaccine research and
development for these pathogens, which involves basic research, vaccine
design, and vaccine evaluation in preclinical challenge models and clinical
trials, is inefficient for these complex intracellular pathogens. We have
established a Global Challenges Research Fund Network for VAccine
deveLopment for complex Intracellular neglecteD pAThogEns, “VALIDATE”,
where we aim to adopt a more flexible, integrated cross-pathogen approach to
accelerate vaccine research and clinical development for these four pathogens,
by cross-pathogen analyses, cross-discipline collaborations, and repeated
integration of data from human and animal studies.
This network provides a unique opportunity to bring together individuals
working on four exemplar complex intracellular neglected pathogens ( , M.tb
 spp.,  and ), which share a commonLeishmania B. pseudomallei M.leprae
lifestyle as pathogens of macrophages, induce similar end-stage pathologies
and alter host immune and metabolic responses. The horizontal collaborations
established throughout this network, together with the provision of a protected
environment for early data sharing, will exploit these biological synergies.  By
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environment for early data sharing, will exploit these biological synergies.  By
interrogating mechanisms that lead from infection to disease, we will be able to
develop common vaccine development strategies for these and other complex
intracellular pathogens.
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Introduction
The global burden of disease and death caused by Mycobacterium 
tuberculosis (M.tb), Leishmania spp, Burkholderia pseudoma-
llei and M.leprae is enormous. Tuberculosis (TB) kills more 
people than any other infectious disease, with 1.7m deaths and 
10.4m new cases in 20161. The significant economic impact of TB 
in low- and middle income countries (LMICs) is due to the dis-
proportionate involvement of the most economically active young 
adults. Furthermore, bovine TB has a very significant effect on 
health and economic development in LMIC2,3. The leishmaniases 
represent a group of heterogeneous diseases caused by intrac-
ellular protozoan parasites of the genus Leishmania. They are 
recognized by the WHO as major neglected diseases of poverty, 
and disproportionately affect populations in LMICs. Approxi-
mately 1.5m new cases occur each year, across 98 countries world-
wide, with 20,000–40,000 deaths4. Canine visceral leishmaniasis 
is not only a veterinary problem but a significant reservoir for 
human disease, notably in Brazil and in countries bordering the 
Mediterranean. As with TB, leishmaniasis and poverty exist in a 
vicious circle, with the economic impact for patients, families and 
communities well documented.
Leprosy and melioidosis also compromise economic productivity 
in LMICs, are difficult to treat and are in need of effective vac-
cination strategies. In 2016, there were 216,108 new leprosy cases 
registered globally5. 14 countries contain 95% of these globally 
reported cases, all of which are in LMICs. Of these, India has the 
greatest number of cases (59%), followed by Brazil (14%) and 
Indonesia (8%). Although the number of cases worldwide con-
tinues to fall, pockets of high prevalence remain in certain areas 
such as Brazil, South Asia (India, Nepal, Bhutan), some parts of 
Africa (Tanzania, Madagascar, Mozambique), and the western 
Pacific. Melioidosis is a disease caused by the Gram-negative soil-
dwelling bacterium Burkholderia pseudomallei6,7. The estimated 
global burden of melioidosis is 165,000 human melioidosis cases/
pa, causing 89,000 deaths7. The burden of disease is in South East 
Asia, where the in-hospital mortality is ~40%8. These estimates of 
incidence for leprosy and melioidosis are likely to be significant 
under-estimates. The development of effective vaccines against 
any or all of these pathogens would have a significant health 
benefit around the world.
What does VALIDATE aim to achieve?
The lack of rapid, coordinated dissemination of information 
between research groups hinders vaccine development. Our 
strategy is to establish a network of multi-disciplinary scien-
tists across the UK and LMICs, who work on vaccine research 
and development for these four complex intracellular neglected 
pathogens. We will take an interdisciplinary approach with immu-
nologists, clinicians, social scientists, veterinarians, epidemi-
ologists, bioinformaticians, mathematical modellers, and animal 
model experts to overcome barriers to progression of vaccine 
development. The coordinated, integrated and iterative sharing 
of data to define protective immunity in animal models, in target 
animal species, and in human experimental medicine studies, across 
complex intracellular pathogens will expedite the development 
of effective vaccines. Our particular focus is on building and 
strengthening cross-pathogen, cross-species, cross-discipline 
and cross- continent collaborations, to foster novel insights and 
new perspectives that lead to an increased understanding of the 
nature of protective immunity. Currently, few horizontal col-
laborations occur between these distinct pathogen research fields. 
VALIDATE will add value by establishing horizontal collabo-
rations whereby innovative research solutions in one field will 
be rapidly disseminated to the other fields. This interaction will 
leverage progress in one field and promote accelerated identifi-
cation of immune mechanisms of protection and evaluation of 
vaccine candidates in human and animal models. Given the many 
common immunological and microbiological features of the 
complex intracellular pathogens selected as the focus of VALI-
DATE, these newly-formed horizontal cross-pathogen collabo-
rations will yield novel insights that will be explored iteratively 
in in vitro and in vivo experiments in animal models and human 
experimental medicine studies. For example, a key feature of 
both TB and leishmaniasis is granuloma formation. Imaging and 
transcriptomics have been used to define the Leishmania granu-
loma; these techniques could be further used to interpret the TB 
granuloma9,10.
To date, VALIDATE has 114 members from 24 countries, 17 of 
these LMICs, and this range of knowledge and experience will 
broaden our scope and ensure relevance. The VALIDATE mem-
bers are selected for their complementary scientific expertise and 
range from internationally recognised leaders in their field to Early 
Career Researchers (ECRs), with students and members of the 
general public who are interested in vaccine research also welcome. 
All scientific members have significant track records in research 
into TB, leishmaniasis, leprosy or melioidosis. Members can come 
from academia, governmental organisations, non-profits, and indus-
try. Specific fields of interest include basic immune mechanisms in 
humans and preclincial animal models, mucosal immunity, immune 
correlates of protection, immunopathogenesis, translational vaccine 
development, mathematical modelling and social science aspects of 
vaccinology.
How will we do it?
VALIDATE has four main activity streams.
Firstly, we are providing relevant funding to our members: as 
pump-priming grants of £20–50k for innovative collaborative 
research projects; training grants to enable our ECRs to attend 
courses, workshops and laboratory exchanges useful for their 
career progression; and as ECR Fellowships to springboard these 
Fellows to scientific independence as new group leaders.
Secondly, VALIDATE is developing a dedicated data-sharing 
portal for members only, which will encourage real-time 
sharing of data, catalysing the application of insights from one 
field into another. The VALIDATE Research Data Analyst is 
tasked with actively searching for data synergies and differences 
where researchers working on different pathogens can learn 
from another, and works with members on existing and arising 
datasets.
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Thirdly we provide Continuing Professional Development (CPD) 
opportunities for our members, including workshops on areas of 
mutual interest, seminars (that are live-streamed online so that 
overseas members can also benefit), and a mentoring scheme 
for ECRs and early PIs open to members across the world – we 
have linked five mentees with their chosen mentors in our first 
round. Scientific research is a valuable economic activity to 
the host country, and we will build sustainable human resource 
capacity within both the UK and low- and middle-income member 
countries.
Finally, we are developing a vibrant and interactive network, facili-
tating the formation of new collaborations and ideas, and speed-
ing the dissemination of useful information amongst our members 
using the full range of communications tools. We have created a 
hub website (www.validate-network.org) where our members can 
easily find information about new research and papers, relevant 
funding calls, events, and training, mentoring and other opportuni-
ties of interest. Interested parties read about our funded work to 
date, while a searchable directory of members on our website is 
facilitating the formation of new collaborations. Our social media 
(@NetworkValidate) raises awareness of these four pathogens and 
VALIDATE’s research through engagement of members, other 
scientists and the lay public. An annual meeting, free to all mem-
bers, furthers our outreach, and boosts existing and potential 
collaborations. There are travel scholarships available for up to 
seven LMIC members each year to facilitate the broadest level of 
attendance.
Summary
VALIDATE provides a unique opportunity for an interdisciplinary 
and integrated approach to vaccine research and development for 
these four exemplar complex intracellular neglected pathogens. 
Sustainable collaborations are being formed and strengthened 
by the resources provided, innovative research has been funded, 
and ECR progression is underway. We are using this platform to 
accelerate vaccine development for our focus pathogens, and are 
building our funding portfolio to ensure sustained progress in these 
critical areas.
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